دورية أكاديمية
An evidence-based, risk-adapted algorithm for antifungal prophylaxis reduces risk for invasive mold infections in children with hematologic malignancies.
| العنوان: | An evidence-based, risk-adapted algorithm for antifungal prophylaxis reduces risk for invasive mold infections in children with hematologic malignancies. |
|---|---|
| المؤلفون: | Dutta A; Department of Pediatrics, Section of Infectious Diseases, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA., Ikwuezunma A; University of Texas Medical School, Rio Grande Valley, Edinburg, Texas, USA., Castellanos MI; Department of Pediatrics, Section of Hematology and Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA., Brackett J; Department of Pediatrics, Section of Hematology and Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA., Reddy K; Department of Pediatrics, Section of Hematology and Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA., Mahajan P; Department of Pediatrics, Section of Hematology and Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA., Marshburn AM; Department of Pediatrics, Division of Pediatric Hospital Medicine, UTHealth Science Center, Houston, Texas, USA., Kamdar K; Department of Pediatrics, Section of Hematology and Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA., Paek H; Department of Pharmacy, Texas Children's Hospital, Houston, Texas, USA., Palazzi DL; Department of Pediatrics, Section of Infectious Diseases, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA., Rabin KR; Department of Pediatrics, Section of Hematology and Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA., Scheurer ME; Department of Pediatrics, Section of Hematology and Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA., Gramatges MM; Department of Pediatrics, Section of Hematology and Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA. |
| المصدر: | Pediatric blood & cancer [Pediatr Blood Cancer] 2021 Dec; Vol. 68 (12), pp. e29228. Date of Electronic Publication: 2021 Jul 16. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: John Wiley Country of Publication: United States NLM ID: 101186624 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1545-5017 (Electronic) Linking ISSN: 15455009 NLM ISO Abbreviation: Pediatr Blood Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Hoboken, N.J. : John Wiley, c 2004- |
| مواضيع طبية MeSH: | Hematologic Neoplasms*/complications , Hematologic Neoplasms*/drug therapy , Mycoses*/etiology , Mycoses*/prevention & control, Algorithms ; Antifungal Agents/therapeutic use ; Child ; Humans ; Retrospective Studies |
| مستخلص: | Background: Children with hematologic malignancies, especially those who receive intensive chemotherapy, are at high risk for invasive mold infections (IMI) that confer substantial mortality. Randomized controlled trials support the use of antifungal prophylaxis with antimold activity as an optimal strategy for risk reduction in this population, but studies outlining the practical application of evidence-based recommendations are lacking. Procedure: We conducted a 15-year, single-institution retrospective review in a diverse cohort of children with hematologic malignancies treated with chemotherapy to determine the incidence of proven or probable IMI diagnosed between 2006 and 2020. Multivariable logistic regression was used to identify host and disease factors associated with IMI risk. We then compared the incidence and type of IMI and related factors before and after 2016 implementation of an evidence-based, risk-adapted antifungal prophylaxis algorithm that broadened coverage to include molds in patients at highest risk for IMI. Results: We identified 61 cases of proven or probable IMI in 1456 patients diagnosed with hematologic malignancies during the study period (4.2%). Implementation of an antifungal prophylaxis algorithm reduced the IMI incidence in this population from 4.8% to 2.9%. Both Hispanic ethnicity and cancer diagnosis prior to 2016 were associated with risk for IMI. Conclusion: An evidence-based, risk-adapted approach to antifungal prophylaxis for children with hematologic malignancies is an effective strategy to reduce incidence of IMI. (© 2021 Wiley Periodicals LLC.) |
| References: | Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15(8):e327-340. Fisher BT, Robinson PD, Lehrnbecher T, et al. Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review. J Pediatric Infect Dis Soc. 2018;7(3):191-198. Lehrnbecher T, Ethier MC, Zaoutis T, et al. International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. Br J Haematol. 2009;147(1):125-128. Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre study group. Eur J Clin Microbiol Infect Dis. 1994;13(4):330-337. Caselli D, Arico M, Michelone G, Cavanna C, Nespoli L, Burgio GR. Antifungal chemoprophylaxis in cancer children: a prospective randomized controlled study. Microbiologica. 1990;13(4):347-351. Fisher BT, Zaoutis T, Dvorak CC, et al. Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia: a randomized clinical trial. JAMA. 2019;322(17):1673-1681. Sawada A, Sakata N, Higuchi B, et al. Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation. Rinsho Ketsueki. 2009;50(12):1692-1699. Lehrnbecher T, Fisher BT, Phillips B, et al. Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. J Clin Oncol. 2020;38(27):3205-3216. Dutta A, Palazzi DL. Candida non-albicans versus Candida albicans fungemia in the non-neonatal pediatric population. Pediatr Infect Dis J. 2011;30(8):664-668. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008;46(12):1813-1821. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56-93. Dare JM, Moppett JP, Shield JP, Hunt LP, Stevens MC. The impact of hyperglycemia on risk of infection and early death during induction therapy for acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2013;60(12):E157-159. Salazar EG, Li Y, Fisher BT, et al. Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States. Br J Haematol. 2016;174(4):591-599. Salzer WL, Jones TL, Devidas M, et al. Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015;62(3):414-418. Lehrnbecher T, Schoning S, Poyer F, et al. Incidence and outcome of invasive fungal diseases in children with hematological malignancies and/or allogeneic hematopoietic stem cell transplantation: results of a prospective multicenter study. Front Microbiol. 2019;10:681. Cesaro S, Tridello G, Castagnola E, et al. Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients. Eur J Haematol. 2017;99(3):240-248. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel). 2017;3(4). Merkhofer RM, Klein BS. Advances in understanding human genetic variations that influence innate immunity to fungi. Front Cell Infect Microbiol. 2020;10:69. Wang SS, Kotecha RS, Bernard A, et al. Invasive fungal infections in children with acute lymphoblastic leukaemia: Results from four Australian centres, 2003-2013. Pediatr Blood Cancer. 2019;66(10):e27915. Castagnola E, Palmisani E, Mesini A, Saffioti C, Micalizzi C, Dufour C. Comment on: Invasive fungal infections in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67(1):e28035. Meryk A, Kropshofer G, Hutter J, et al. Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia. Br J Haematol. 2020;191(5):816-824. Fisher BT, Ross RK, Roilides E, et al. Failure to validate a multivariable clinical prediction model to identify pediatric intensive care unit patients at high risk for candidemia. J Pediatric Infect Dis Soc. 2016;5(4):458-461. Ananda-Rajah MR, Grigg A, Slavin MA. Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis. Mycopathologia. 2008;166(2):83-86. Georgiadou SP, Pongas G, Fitzgerald NE, et al. Invasive mold infections in pediatric cancer patients reflect heterogeneity in etiology, presentation, and outcome: a 10-year, single-institution, retrospective study. Journal of the Pediatric Infectious Diseases Society. 2012;1(2):125-135. Foster CE, Edwards MS, Brackett J, Schady DA, Healy CM, Baker CJ. Trichosporonosis in pediatric patients with a hematologic disorder. J Pediatric Infect Dis Soc. 2018;7(3):199-204. Elgarten CW, Aplenc R. Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy. Current Opinion in Pediatrics. 2020;32(1):57-66. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541-1552. Science M, Robinson PD, MacDonald T, Rassekh SR, Dupuis LL, Sung L. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatric Blood & Cancer. 2014;61(3):393-400. Dvorak CC, Fisher BT, Sung L, et al. Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data. Pediatric Blood & Cancer. 2012;59(1):21-26. |
| فهرسة مساهمة: | Keywords: antifungal prophylaxis; invasive mold infection; leukemia; lymphoma |
| المشرفين على المادة: | 0 (Antifungal Agents) |
| تواريخ الأحداث: | Date Created: 20210716 Date Completed: 20220415 Latest Revision: 20220415 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1002/pbc.29228 |
| PMID: | 34268879 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1545-5017 |
|---|---|
| DOI: | 10.1002/pbc.29228 |